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SUMMARY – Chronic obstructive pulmonary disease (COPD) and heart failure (HF) both are 
global epidemics with substantial burden on morbidity and mortality. Th ey present major challenges 
to healthcare providers and often coexsist. Multiple interactions exist between these conditions. 
COPD is often responsible for delayed diagnosis of HF and vice versa, since both conditions have 
similar symptoms such as dyspnea and poor exercise tolerance based on the skeletal myopathic 
 response rather than the primary organ failure. Patients with COPD also have an increased risk of 
developing HF and higher hospitalization and death rates compared with HF patients without 
COPD. Echocardiography and pulmonary function tests along with natriuretic peptides should be 
performed and carefully interpreted. Diagnostic assessment of both conditions present in the same 
patient is often diffi  cult, but therapeutic approach is also often non-adherent to current guidelines. For 
example, patients with coexisting COPD and HF receive beta-blockers at disappointingly low rates 
below 20%. Closer collaboration between cardiologists and pulmonologists is required for better iden-
tifi cation and management of concurrent COPD and HF.
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Introduction
Chronic obstructive pulmonary disease (COPD) is 
projected to be the fi fth leading cause of morbidity 
and third leading cause of mortality worldwide by 
20201. Although major advances in the understanding 
of COPD have been made in recent decades, the het-
erogeneity of clinical phenotypes, as well as the vari-
ability of clinical course continue to be only partially 
explained. Th e Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) was launched in 1997 in 
order to improve the understanding of the underlying 
mechanisms of the disease and global awareness of 
COPD, as well as to reach expert recommendation on 
the prevention, diagnosis and treatment of COPD. In 
the fi rst GOLD Workshop Summary Report in 2001, 
COPD is defi ned as a disease state characterized by 
airfl ow limitation that is not fully reversible and is usu-
ally progressive. It has also been stated that the disease 
is associated with an abnormal infl ammatory response 
of the lungs to noxious particles or gases.
Th e initial COPD ranking system was based on 
post-bronchodilator spirometry and it has been proven 
as a useful indicator for treatment, as well as a reliable 
value to be compared in clinical studies. In other 
words, in the beginning of our understanding of 
COPD, the rigidity (and simplicity) of the staging sys-
tem proved useful. However, it has become evident 
that the relationship between forced expiratory vol-
ume in the fi rst second (FEV
1
) and symptoms is far 
from perfect and that exacerbations are independently 
associated with a more rapid function decline and in-
creased mortality risk. Moreover, it seems that high 
symptom scores may originate not only from airfl ow 
limitation, but also from comorbidities. For example, 
in the ECLIPSE study, a subgroup of patients with 
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the highest prevalence of comorbidities also had signs 
of persistent systemic infl ammation2.
Consequently, the GOLD Science Committee ad-
opted the novel approach to annual reviews of the ever 
growing published data with two major revisions of the 
GOLD document in 2007 and 2011. Th e GOLD 2011 
assessment proposal includes two additional major cri-
teria: the impact of the disease as perceived by the pa-
tient and the risk of future exacerbations. Patients are 
divided into four major categories: less symptoms and 
low risk (group A), more symptoms and low risk (group 
B), less symptoms and high risk (group C) and more 
symptoms and high risk (group D)3.
In clinical practice, the list of variables to be in-
cluded in comprehensive approach to the individual 
patient is even longer, including lifestyle characteris-
tics such as persistent smoking or the level of physical 
activity, biological markers of the disease activity and, 
very important, additional clinical outcomes such as 
comorbidities or lung hyperinfl ation.
COPD and Heart Failure
Chronic obstructive pulmonary disease is the fourth 
commonest cause of death worldwide, and the future 
does not seem bright, as by the year 2020 COPD will be 
ranked third. COPD and chronic heart failure (CHF) 
are both global epidemics and have common determi-
nants (smoking and chronic infl ammation), which have 
been shown to play major roles in the pathogenesis of 
both diseases. Patients with COPD die mainly from 
non-respiratory diseases: 25% from cardiovascular dis-
eases, 20%-33% from cancer (mainly lung cancer), and 
4%-35% from respiratory diseases, mainly respiratory 
failure during exacerbations4.
Among the comorbid conditions associated with 
CHF, COPD is one that most often delays correct di-
agnosis of CHF and is responsible for nonadherence 
to current treatment guidelines, such as beta blockade. 
On the other hand, until recently it was often enough 
that only self-reported COPD was considered suffi  -
cient to establish the diagnosis. Still, few reports have 
addressed this often ignored combination, and fewer 
still from the pneumonologist’s point of view.
Prevalence of Coexisting COPD and CHF
In most studies, the estimated prevalence of COPD 
in patients with CHF ranges from 11% to 52%5-12. In 
recent studies, the prevalence is notably higher. Th e risk 
ratio of developing heart failure (HF) is 4.5 (95% confi -
dence interval (95% CI) 4.25-4.95) in COPD patients 
after adjustment for cardiovascular risk factors and 
compared with age-matched controls13. In the 
ECLIPSE study, the overall prevalence of HF was 7%, 
but it increased with the severity of airfl ow limitation14.
At least part of the explanation, besides the common 
risk factors and a rich body of evidence for chronic sys-
temic infl ammation and endothelial dysfunction, lies in 
global aging of the population; almost half of the people 
aged ≥65 have at least three medical conditions15.
All these epidemiological data must be considered 
with some degree of caution because of the reported 
signifi cant disparities in using confi rmatory diagnostic 
tests amongst practicing clinicians. Up to one-third of 
patients labeled with COPD do not fulfi ll GOLD cri-
teria for the diagnosis. A recent US study showed that 
among 219 patients discharged from a tertiary centre 
with both diagnoses of COPD and HF, 82% received 
echocardiography, as opposed to only 36% of patients 
who received pulmonary function testing, which is 
much less expensive and time consuming than com-
prehensive echocardiography16. In their prospective 
REPENSAR study, Macchia et al. found that only 
6.5% of cardiologists and 12% of pulmonologists had 
certifi ed or ruled out COPD in patients with CHF, or 
vice versa17. COPD independently predicted failure of 
the ejection fraction of left ventricle (EFLV) assess-
ment by echocardiography during hospital stay in the 
Italian TEMISTOCLE study18.
Chronic obstructive pulmonary disease strongly pre-
dicts hospitalization rate and duration, and non-cardio-
vascular mortality in HF patients with 5-year mortality 
as high as 69% compared to 58% in patients without 
COPD. Also, respiratory infections are associated with 
cardiac decompensation in 10%-16% of admissions19. 
On the other hand, the prevalence of unrecognized HF 
in COPD patients presenting to emergency depart-
ment with acute dyspnea is 20.9%, and unrecognized 
HF is a frequent cause of weaning diffi  culties in COPD 
patients requiring mechanical ventilation due to severe 
acute exacerbation of the disease20.
Typical Clinical Feature: Dyspnea
Dyspnea is the most disabling symptom of COPD, 
which originates from decrease in the capacity of re-
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spiratory muscles to meet an increased mechanical 
load. Several diff erent mechanisms contribute to this 
imbalance.
Patients with COPD must generate more negative 
intrathoracic pressures in order to achieve adequate al-
veolar ventilation. Th e pressure output during resting 
breathing can be more than three times higher com-
paring with healthy subjects21. Th is means higher oxy-
gen cost of respiration accompanied with less effi  cien-
cy. Also, inspiratory fl ow resistance is increased22, loss 
of elastic recoil causes higher relaxation volume, min-
ute ventilation is increased up to 50% even during rest-
ing breathing, and expiratory fl ow is limited with de-
layed lung emptying23,24.
Hyperinfl ation decreases the length of the dia-
phragm and of the rib cage muscles with a signifi cant 
decrease in the length of the zone of diaphragmatic 
apposition, so the diaphragmatic contraction is less ef-
fective25,26. Furthermore, diaphragmatic curvature is 
also decreased. In the situation when end-expiratory 
lung volume lies above 70% of the predicted total lung 
capacity, inspiratory muscles have to work not only 
against the elastic recoil of the lungs, but also against 
elastic recoil of the thoracic cage27.
About half of the patients with moderate-to-severe 
COPD have parallel reductions in maximal inspiratory 
and expiratory muscle strength, possibly due to the gen-
eralized muscle weakness27,28. Th e mechanisms contrib-
uting to this generalized muscle wasting are malnutri-
tion, altered infl ammatory cytokine profi le with high 
plasma levels of tumor necrosis factor alpha (TNF-a) 
with activation of the ubiquitin-proteasome proteolytic 
pathway29-31, electrolite and blood gas abnormalities, 
HF29, weight loss28, and steroid myopathy32.
Inspiratory muscle weakness in patients with CHF 
is a result of a complex interplay between decreased 
total number of diaphragmatic actin-myosin cross-
bridges33, reduction in type IIb fi bers34, decreased re-
gional blood fl ow, activation of the ubiquitin-protea-
some proteolytic pathway by TNF-a, decrease in vari-
ous oxidative enzymes, size and number of mitochon-
dria35, atrophy of the limb muscle fi bers, postcapillary 
pulmonary hypertension with compensatory vascular 
remodeling, bronchial congestion, decreased lung 
compliance and consequently increased work of the 
diaphragm up to threefold36-37 and, to some extent, hy-
perpnea that could predispose to hyperinfl ation38,39.
Of note, patients with COPD have similar symp-




Transthoracic echocardiography is often infl uenced 
by the poor acoustic windows in patients with emphy-
sema; in a recent study, inadequate visualization caused 
by air trapping caused unsatisfactory results in 10.4% 
of all examined patients with COPD40,41. Th is propor-
tion is even greater in patients with severe and very 
severe airfl ow obstruction in emphysema phenotype42.
In transesophageal echocardiography, the trans-
ducer located behind the heart enables continuous vi-
sualization of all four heart chambers without hin-
drance from lung even during mechanical ventilation. 
Of note, during transesophageal echocardiography, as 
well as in interventional cardiology and pulmonology, 
noninvasive ventilation can reduce the need for deep 
sedation or general anesthesia and prevent respiratory 
depression induced by deep sedation43.
Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging is the accept-
ed reference standard for estimation of left ventricular 
(LV) volumes and ejection fraction. It is especially rec-
ommended in the evaluation of LV function in pa-
tients with inadequate visualization on echocardio-
graphic images and could additionally estimate myo-
cardial fi brosis and predict the risk of arrhythmias in 
COPD patients44.
Natriuretic peptides
Natriuretic peptides are targeted at protecting the 
cardiovascular system from the eff ects of volume over-
load. Both atrial natriuretic peptide (ANP) and B-type 
natriuretic peptide (BNP) induce vasodilatation, natri-
uresis and diuresis. BNP is secreted in bursts and has 
minimal storage, unlike ANP which can be released 
with minor triggers. In the setting of pressure overload 
or volume expansion, the synthesis of pre-proBNP in 
ventricular myocardium is initiated and afterwards the 
cleavage to proBNP and then to BNP and inactive 
NTproBNP follows45.
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Both BNP and NTproBNP are useful for exclud-
ing HF in subjects presenting with acute or worsening 
dyspnea. Th ey also provide prognostic information as 
every 100 pg/mL increase in BNP level is associated 
with 35% increased death risk46. Also, BNPs are useful 
in monitoring the eff ects of therapeutic interventions 
and may be used as a tool for screening for subclinical 
forms of HF. Th e BNP Consensus Panel Guidelines 
state that BNP levels lower than 100 pg/mL have high 
negative and levels higher than 500 pg/mL high posi-
tive predictive value for HF. Increased levels of both 
BNP and NTproBNP are associated with female gen-
der, advanced age, acute coronary syndrome without 
HF, sepsis, acute respiratory distress syndrome 
(ARDS) and right HF45.
Th erapeutic Challenges
ACE inhibitors or ARBs
Angiotensin-converting enzyme (ACE) inhibitors 
are the cornerstone of treatment in CHF. Moreover, 
ACE inhibition has been demonstrated to prevent 
smooth muscle atrophy and improve respiratory mus-
cle strength in patients with HF47, and these eff ects 
could be especially interesting in patients with con-
comitant COPD. Also, cross-sectional data from 2431 
hypertensive subjects found that lower limb muscle 
mass was larger in the ACE inhibitor group in a man-
ner proportional to the length of use48. However, in a 
recent small randomized controlled study, Shrikrishna 
et al. found that fosinopril treatment for 3 months did 
not alter muscle atrophy signaling or exercise perfor-
mance in COPD patients with quadriceps weakness49.
Andreas et al. evaluated the eff ects of the angioten-
sin II receptor blocker irbesartan given over 4 months 
in 60 patients with COPD and FEV
1 
of less than 50% 
of the predicted value and without obvious cardiovas-
cular disease that would necessitate administration of 
an ACE inhibitor or angiotensin receptor blocker. In 
this study, irbesartan did not exert signifi cant eff ect on 
the primary end-point maximum inspiratory pressure, 
but there was a trend towards total lung capacity re-
duction – a fi nding that probably deserves prospective 
investigation50.
In conclusion, despite extensive data on the eff ects 
of ACE and angiotensin II type-1 receptor inhibition 
(ARB) on systemic infl ammation and tissue metabo-
lism, the body of evidence on the potential eff ects on 
pulmonary infl ammation, architecture and vasculature 
or skeletal muscle functional capacity in COPD, espe-
cially in the face of reduced oxygen delivery, is still in-
suffi  cient. Nevertheless, due to the improved outcome 
of HF, ACE inhibitors or ARBs should not be denied 
in concomitant COPD. In the OPTIMIZE-HF co-
hort, patients with COPD were less likely to be started 
on ACE-Is/ARBs and aldosterone antagonists during 
hospital stay and were also more likely to have their 
ACE-Is/ARBs discontinued51. It should be empha-
sized that the regular use of ACE inhibitors does not 
induce bronchospasm or increased risk of cough in 
COPD patients.
Beta blockers
Beta blockers are still generally underused in CHF 
patients, especially those with concomitant COPD. 
According to the evidence from 12,440 patients in the 
ESC Heart Failure Long-Term Registry, beta blockers 
were prescribed to 72% of hospitalized patients with 
HF and 89% of patients in the outpatient setting, but 
only 17% of patients received targeted daily doses52. In 
a recent large sample from primary care in Scotland 
(N=377,439), the prevalence of established COPD in 
patients with HF was 25%, but only a small minority 
(18%) of COPD patients received beta blockers53.
Beta-1 blockers (B1B) have 20-fold higher affi  nity 
for beta-1 receptors (B1R) than beta-2 receptors 
(B2R) and, although they tend to lose sensitivity at the 
high end of dose ranging, patients with COPD are 
generally free of adverse respiratory eff ects with un-
changed FEV
1
. Selective B1B do not attenuate B2R 
agonist-induced bronchodilatatory eff ects and may ac-
tually be benefi cial in COPD by enhancing sensitivity 
to exogenous beta-adrenergic stimulation. Also, recent 
large observational studies provide some evidence that 
concomitant long-term use of inhaled antimuscarinic 
agents or beta agonists along with cardioselective beta 
blockers actually reduces mortality rates and the risk of 
exacerbations in patients with COPD54,55. According 
to a systematic review by Etminan et al. of nine retro-
spective cohort studies, beta blockers reduce mortality 
in COPD, most probably due to their cardioprotective 
eff ects56. However, several types of biases may have af-
fected the cited results and one should note that stud-
ies with negative results are much less likely to be pub-
lished.
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Despite the data collected from meta-analyses, 
which strongly suggest that selective B1B should not 
be withheld in patients with mild to severe COPD 
and HF because their benefi ts by far outweigh the 
risks57,58, beta blockers are less prescribed before 
 admission (21.1% vs. 23.8%, p=0.055) in COPD 
 patients, and remain underutilized at discharge 
(p<0.001)59.
Carvedilol is the only non-cardioselective beta 
blocker approved for treating HF. Since there are no 
robust data supporting the safety in patients with 
moderate or severe airways disease, it should be avoid-
ed when possible in patients with COPD, especially 
during acute exacerbations.
In conclusion, cardioselectivity is paramount, and 
therefore metoprolol, bisoprolol and in particular 
nebivolol should be the fi rst choice treatment.
Inhaled beta-2 agonists
For decades, inhaled beta-2 agonists were strongly 
associated with adverse cardiac eff ects in COPD pa-
tients with pre-existing cardiovascular disease and an 
increased risk of CHF decompensation (adjusted OR 
3.42; 95% CI 1.99 to 5.86), also with all-cause mortal-
ity in patients with CHF60. Au et al. found direct as-
sociation between the number of canisters of beta ago-
nist used and the risk of and death from all causes, 
suggesting caution using beta agonists in patients with 
left ventricular systolic dysfunction61. One might argue 
that the use of beta agonists, short-acting beta agonists 
(SABA) in particular, in acute setting merely refl ects 
the degree of dyspnea. In the ACQUIP case-control 
study, beta agonists in patients with HF were associ-
ated with the risk of hospitalization, but adjustment 
for cardiovascular morbidity, age, beta blocker use, 
COPD severity and smoking burden made the diff er-
ence nonsignifi cant62. In short, the poor patient out-
comes attributed to beta agonists may actually refl ect 
symptom burden in COPD.
Since long-acting beta agonists (LABA) or/and 
long-acting antimuscarinic agents (LAMA) are the 
cornerstone of COPD treatment in all stages for de-
creasing exacerbation rates, improving lung function 
and quality of life, prescribing only SABA and/or 
short-acting muscarinic antagonists (SAMA) for symp-
tom relief and avoiding treating COPD when coexist-
ing with HF would be as erroneous as denying beta 
blockers to patients with HF.
Th ere is additional concern of triggering supraven-
tricular and ventricular arrhythmias by LABA, LAMA 
and their combinations. Multifocal atrial tachycardia 
(MAT), atrial fi brillation and ventricular arrhythmias 
often complicate the course of COPD, in particular 
during acute exacerbations. MAT is often associated 
with the use of theophylline, pulmonary embolism, 
hypoxemia, and also other disorders such as hypokale-
mia or hypomagnesemia, and chronic renal failure63. 
Th e largest trial of 1429 patients with COPD found 
that the administration of formoterol or salmeterol, 
the two most often administered LABAs, did not re-
sult in a statistically signifi cant increase in atrial ar-
rhythmias64.
One of the most important risk factors of arrhyth-
mias is acute respiratory failure or, in particular, wors-
ening of chronic respiratory failure during acute exac-
erbations. One of the most important decisions in the 
acute clinical setting is well-timed noninvasive venti-
lation.
Conclusion
Both HF and COPD are global epidemics, espe-
cially in the elderly. Both diseases are chronic, progres-
sive, and share many common pathways of low grade 
systemic infl ammation. Th e prevalence of coexisting 
HF and COPD is yet unknown and most certainly 
underestimated. Understanding both diseases with the 
use of proper diagnostic tools is mandatory in order to 
achieve earlier treatment and better long-term prog-
nosis. Concurrent COPD may play part of the missing 
puzzle in the complex pathophysiology of HF, and vice 
versa. Considering the high prevalence of ventricular 
dysfunction in COPD, routine assessment with either 
BNP or echocardiography should be considered in 
COPD patients. On the other hand, pulmonary func-
tion tests should be performed in all HF patients. 
Th erefore, closer collaboration between pulmonolo-
gists and cardiologists should be warranted in the fu-
ture. Also, there is an urgent need for large prospective 
randomized trials on long-term eff ects of diff erent 
classes of currently recommended drugs including pa-
tients with more advanced disease(s), including those 
with frequent exacerbations, patients with severe im-
pairment of lung function, heavy symptoms, or those 
with the asthma and COPD overlap syndrome.
Jelena Ostojić and H. Pintarić COPD and heart failure
274 Acta Clin Croat, Vol. 56, No. 2, 2017
References
 1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; 
GOLD Scientifi c Committee. Global strategy for the diagno-
sis, management, and prevention of chronic obstructive pulmo-
nary disease. NHLBI/WHO Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) Workshop summary. Am 
J Respir Crit Care Med. 2001;163(5):1256-76.
 2. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, 
Müllerova H, et al. Characteristics, stability and outcomes of 
the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur 
Respir J. 2013;42(3):636-46, http://dx.doi.org/10.1183/0903
1936.00195212.
 3. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, An-
zueto A, et al. Global strategy for the diagnosis, management, 
and prevention of chronic obstructive pulmonary disease: 
GOLD executive summary, Am J Respir Crit Care Med. 2013;
187(4):347-65, https://doi.org/10.1164/rccm.201204-0596PP.
 4. Fabbri LM, Luppi F, Beghe B. Complex chronic comorbidities 
of COPD. Eur Respir J. 2008;31:204-12, https://doi.org/ 
10.1183/09031936.00114307.
 5. Bangdiwala Sl, Weiner DH, Bourassa MG. Studies of Left 
Ventricular Dysfunction (SOLVD) Registry: rationale, design, 
methods and description of baseline characteristics. Am J Car-
diol. 1992;70:347-53.
 6. Vaccarino V, Chen YT, Wang Y. Sex diff erences in the clinical 
care and outcomes of congestive heart failure in the elderly. Am 
Heart J. 1999;138:835-42, https://doi.org/ 10.1016/j.ahj.2004.
06.008.
 7. Baker DW, Einstadter D, Th omas C. Mortality trends for 
23,505 Medicare patients hospitalized with heart failure in 
Northeast Ohio, 1991 to 1997. Am Heart J. 2003;146:258-64.
 8. Kosibrood M, Lichtman JH, Heidenreich PA. National trends 
in outcomes among elderly patients with heart failure. Am J 
Med. 2006;119:616-7.
 9. Havranek EP, Masoudi PA, Westfall KA. Spectrum of heart 
failure in older patients: results from the National Heart Fail-
ure project. Am Heart J. 2002;143:412-7.
10. Rathore SS, Foody JM, Wang Y. Sex, quality of care and out-
comes of elderly patients hospitalized with heart failure: fi nd-
ings from the National Heart Failure project. Am Heart J. 
2005;149:121-8, https://doi.org/ 10.1016/j.ahj.2004.06.008.
11. Milacić N, Milacić B, Milojković M, Ljubisavljević S, Vodo-
pić S, Hasanbegović M, et al. Correlation of C-reactive protein 
and COPD severity. Acta Clin Croat. 2016;55(1):41-8, https://
doi.org/ 10.20471/acc.2017.56.01.01.
12. Lee DS, Austin PC, Rouleau JL. Predicting mortality among 
patients hospitalized for heart failure: derivation and validation 
of a clinical model. J Am Med Assoc. 2003;290:2581-7, https://
doi.org/ 10.1001/jama.290.19.2581.
13. Curkendall SM, DeLuise C, Jones JK. Cardiovascular disease 
in patients with chronic obstructive lung disease, Saskatchewan 
Canada cardiovascular disease in COPD patients. Ann Epi-
demiol. 2006;16:63-70, https://doi.org/10.1016/j.annepidem.
2005.04.008.
14. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, 
Lomas DA, et al. Characterisation of COPD heterogeneity in 
the ECLIPSE cohort. Respir Res. 2010;11:122, https://doi.
org/10.1186/1465-9921-11-122.
15. Fabbri LM, Luppi F, Beghe B. Complex chronic comorbidities 
of COPD. Eur Respir J 2008;31:204-12, https://doi.org/
10.1183/09031936.00114307.
16. Damarla M, Celli BR. Discrepancy in the use of confi rmatory 
tests in patients hospitalized with the diagnosis of chronic ob-
structive lung disease or congestive heart failure. Respir Care. 
2006;51:1120-4.
17. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani 
PD, Gimeno G, Arakaki D, et al. Unrecognised ventricular 
 dysfunction in COPD. Eur Respir J. 2012; 39(1):51-8, https://
doi.org/ 10.1183/09031936.00044411.
18. Di Lenarda A, Scherillo M, Maggioni AP, Acquarone N, Am-
brosio GB, Annicchiarico M, et al. Current presentation and 
management of heart failure in cardiology and internal medi-
cine hospital units: a tale of two worlds – the TEMISTOCLE 
study. Am Heart J. 2003;146(4):E12, https://doi.org/10.1016/
S0002-8703(03)00315-6.
19. Rusinaru D, Saaidi I, Godard S. Impact of chronic obstructive 
lung disease on long-term outcome of patients hospitalized for 
heart failure. Am J Cardiol. 2008;101:353-8, https://doi.org/
10.1016/j.amjcard.2007.08.046.
20. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, 
Harjola VP, et al. EuroHeart failure survey II (EHFS II): a sur-
vey on hospitalized acute heart failure patients: description of 
population. Eur Heart J. 2006;27:2725-36, https://doi.org/
10.1093/eurheartj/ehl193.
21. Laghi F, Jubran A, Topeli A, Fahey PJ, Garrity ER Jr, Arcidi 
JM, et al. Eff ect of lung volume reduction surgery on neurome-
chanical coupling of the diaphragm. Am J Respir Crit Care 
Med. 1998;157:475-83.
22. Offi  cer TM, Pellegrino R, Brusasco V, Rodarte JR. Measure-
ment of pulmonary resistance and dynamic compliance with 
airway obstruction. J Appl Physiol. 1998;85:1982-8, https://
doi.org/10.1590/S1807-59322009000700008.
23. Tobin MJ, Chadha TS, Jenouri G, Birch SJ, Gazeroglu HB, 
Sackner MA. Breathing patterns. 1. Normal subjects. Chest. 
1983;84:202-5.
24. Tobin MJ, Chadha TS, Jenouri G, Birch SJ, Gazeroglu HB, 
Sackner MA. Breathing patterns. 2. Diseased subjects. Chest. 
1983;84:286-94.
25. Cassart M, Pettiaux N, Gevenois PA, Paiva M, Estenne M. Ef-
fect of chronic hyperinfl ation on diaphragm length and surface 
area. Am J Respir Crit Care Med. 1997;156:504-8, https://
doi.org/10.1164/ajrccm.156.2.9612089.
26. Laghi F, Harrison MJ, Tobin MJ. Comparison of magnetic and 
electrical phrenic nerve stimulation in assessment of diaphrag-
matic contractility. J Appl Physiol. 1996;80:1731-42.
Jelena Ostojić and H. Pintarić COPD and heart failure
Acta Clin Croat, Vol. 56, No. 2, 2017 275
27. Rochester DF, Braun NM. Determinants of maximal inspira-
tory pressure in chronic obstructive pulmonary disease. Am 
Rev Respir Dis. 1985;132:42-7.
28. Decramer M, de Bock V, Dom R. Functional and histologic 
picture of steroid-induced myopathy in chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med. 1996;153:
1958-64, https://doi.org/10.1164/ajrccm.153.6.8665061.
29. Hughes PD, Polkey MI, Harrus ML, Coats AJ, Moxham J, 
Green M. Diaphragm strength in chronic heart failure. Am J 
Respir Crit Care Med. 1999;160:529-34, https://doi.org/
10.1164/ajrccm.160.2.9810081.
30. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF. 
Physiologic eff ects of nutritional support and anabolic steroids in 
patients with chronic obstructive pulmonary disease: a placebo-
controlled randomized trial. Am J Respir Crit Care Med. 1995;
152:1268-74, https://doi.org/10.1371/journal.pone.0084855.
31. Li YP, Reid MB. NF-kB mediates the protein loss induced by 
TNF-a in diff erentiated skeletal muscle myotubes. Am J 
Physiol Regul Integr Comp Physiol. 2000; 279:R1165-70.
32. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticoste-
roids contribute to muscle weakness in chronic airfl ow obstruc-
tion. Am J Respir Crit Care Med. 1994;150:11-6, https://doi.
org/10.1164/ajrccm.150.1.8025735.
33. Lecarpentier Y, Coirault C, Lerebours G, Desche P, Scalbert E, 
Lambert F, et al. Eff ects of angiotensin converting enzyme in-
hibition on crossbridge properties of diaphragm in cardiomyo-
pathic hamsters of the dilated bio 53-58 strain. Am J Respir 
Crit Care Med. 1997;155:630-6, https://doi.org/10.1164/ajrc-
cm.155.2.9032205.
34. Sieck GC, Fournier M. Diaphragm motor unit recruitment 
during ventilatory and nonventilatory behaviors. J Appl Physi-
ol. 1989;66:2539-45.
35. Drexler H, Riede U, Munzel T, König H, Funke E, Just H. 
Alterations of skeletal muscle in chronic heart failure. Circula-
tion. 1992;85:1751-9.
36. Mancini DM, Henson D, LaManca J, Levine S. Respiratory 
muscle function and dyspnea in patients with chronic conges-
tive heart failure. Circulation. 1992;86:909-18.
37. Lenique F, Habis M, Lofaso F, Dubois-Randé JL, Harf A, 
Brochard L. Ventilatory and hemodynamic eff ects of continu-
ous positive airway pressure in left heart failure. Am J Respir 
Crit Care Med. 1997;155:500-5, https://doi.org/10.1164/ajrc-
cm.155.2.9032185.
38. O’Donnell DE, D’Arsigny C, Raj S, Abdollah H, Webb KA. 
Ventilatory assistance improves exercise endurance in stable 
congestive heart failure. Am J Respir Crit Care Med. 1999;
160:1804-11, https://doi.org/10.1164/ajrccm.160.6.9808134.
39. Duguet A, Tantucci C, Lozinguez O, Isnard R, Th omas D, 
Zelter M, et al. Expiratory fl ow limitation as a determinant of 
orthopnea in acute left heart failure. J Am Coll Cardiol. 2000;
35:690-700.
40. Wheeldon NM, MacDonald TM, Flucker CJ. Echocardiogra-
phy in chronic heart failure in the community. Q J Med. 1993;
86:17-23.
41. Rutten FH, Moons KG, Cramer MJ. Recognising heart failure 
in elderly patients with stable chronic obstructive pulmonary 
disease in primary care: cross sectional study. BMJ. 2005;
331:1379, https://doi.org/10.1136/bmj.38664.661181.55.
42. Vizza CD, Lynch JP, Ochoa LL. Right and left ventricular dys-
function in patients with severe pulmonary disease. Chest. 
1998;113:576-83.
43. Ambrosino N, Guarracino F. Unusual applications of noninva-
sive ventilation. Eur Respir J. 2011;38(2):440-9, https://doi.
org/10.1183/09031936.00192810.
44. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan 
M, et al. Cardiovascular magnetic resonance, fi brosis, and prog-
nosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;
48(10):1977-85, https://doi.org/10.1016/j.jacc.2006.07.049.
45. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Car-
diol. 2007;50:2357-68.
46. Doust JA, Pietrzak E, Dobson A. How well does B-type natri-
uretic peptide predict death and cardiac events in patients with 
heart failure: systematic review. BMJ. 2005;330:625, https://
doi.org/10.1136/bmj.330.7492.625.
47. Coirault C, Hagege A, Chemla D. Angiotensin-converting en-
zyme inhibitor therapy improves respiratory muscle strength in 
patients with heart failure. Chest. 2001;119:1755-60.
48. Di Bari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, 
Newman A, Harris TB, et al. Antihypertensive medications and 
diff erences in muscle mass in older persons: the Health, Aging 
and Body Composition Study. J Am Geriatr Soc. 2004;52(6):
961-6, https://doi.org/10.1111/j.1532-5415.2004.52265.x.
49. Shrikrishna D, Tanner RJ, Lee JY, Natanek A, Lewis A, Mur-
phy PB, et al. A randomized controlled trial of angiotensin-
converting enzyme inhibition for skeletal muscle dysfunction 
in COPD. Chest. 2014;146(4):932-40, https://doi.org/10.
1378/chest.13-2483.
50. Andreas S, Herrmann-Lingen C, Raupach T, Lüthje L, Fa-
bricius JA, Hruska N, et al. Angiotensin II blockers in obstruc-
tive pulmonary disease: a randomised controlled trial. Eur 
Respir J. 2006;27(5):972-9, https://doi.org/10.1183/09031936
.06.00098105.
51. O’Connor CM, Abraham WT, Albert NM, Clare R, Gattis 
Stough W, Gheorghiade M, et al. Predictors of mortality after 
discharge in patients hospitalized with heart failure: an analysis 
from the Organized Program to Initiate Lifesaving Treatment 
in Hospitalized Patients with Heart Failure (OPTIMIZE-
HF). Am Heart J. 2008;156(4):662-73, https://doi.org/10.
1016/j.ahj.2008.04.030.
52. Maggioni AP, Anker SD, Dahlström U, Filippatos G, Poni-
kowski P, Zannad F, et al. Are hospitalized or ambulatory pa-
tients with heart failure treated in accordance with European 
Society of Cardiology guidelines? Evidence from 12,440 pa-
tients of the ESC Heart Failure Long-Term Registry. Eur J 
Heart Fail. 2013;15(10):1173-84.
53. Hawkins NM, Jhund PS, Simpson CR, Petrie MC, Macdonald 
MR, Dunn FG, et al. Primary care burden and treatment of 
Jelena Ostojić and H. Pintarić COPD and heart failure
276 Acta Clin Croat, Vol. 56, No. 2, 2017
patients with heart failure and chronic obstructive pulmonary 
disease in Scotland. Eur J Heart Fail. 2010;12(1):17-24.
54. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. 
Eff ect of beta blockers in treatment of chronic obstructive pul-
monary disease: a retrospective cohort study. BMJ. 2011;342:
d2549.
55. Rutten FH, Zuithoff  NP, Hak E, Grobbee DE, Hoes AW. 
Beta-blockers may reduce mortality and risk of exacerbations 
in patients with chronic obstructive pulmonary disease. Arch 
Intern Med. 2010;170(10):880-7, https://doi.org/10.1001/
archinternmed.2010.112.
56. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker 
use and COPD mortality: a systematic review and meta-anal-
ysis. BMC Pulm Med. 2012;12:48, https://doi.org/10.1186/
1471-2466-12-48.
57. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-block-
ers for chronic obstructive pulmonary disease. Cochrane Data-
base Syst Rev. 2005;4:CD003566, https://doi.org/10.1002/
14651858.CD003566.pub2
58. Van der Woude HJ, Zaagsma J, Postma DS. Detrimental ef-
fects of beta-blockers in COPD: a concern for nonselective 
beta-blockers. Chest. 2005;127:818-24.
59. Parissis JT, Andreoli C, Kadoglou N, Ikonomidis I, Farmakis 
D, Dimopoulou I, et al. Diff erences in clinical characteristics, 
management and short-term outcome between acute heart 
failure patients with chronic obstructive pulmonary disease and 
those without this co-morbidity. Clin Res Cardiol. 2014;
103(9):733-41, https://doi.org/10.1007/s00392-014-0708-0.
60. Martin RM, Dunn NR, Freemantle SN. Risk of nonfatal car-
diac failure and ischemic heart disease with long acting B2R-
agonists. Th orax. 1998;53:558-62.
61. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn 
SD. Risk of mortality and heart failure exacerbations associated 
with inhaled beta-adrenoceptor agonists among patients with 
known left ventricular systolic dysfunction. Chest. 2003;123
(6):1964-9.
62. Au DH, Udris EM, Curtis JR, et al. Association between 
chronic heart failure and inhaled beta-2-adrenoceptor agonists. 
Am Heart J. 2004;148(5):915-20, https://doi.org/10.1016/j.
ahj.2004.03.048.
63. McCord J, Borzak S. Multifocal atrial tachycardia. Chest. 
1998;113:203.
64. Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhyth-
mias in patients with chronic obstructive pulmonary disease 
(COPD): occurrence frequency and the eff ect of treatment 
with the inhaled long-acting beta2-agonists arformoterol and 
salmeterol. Medicine (Baltimore). 2008;87(6):319-28.
Sažetak
KRONIČNA OPSTRUKTIVNA PLUĆNA BOLEST I ZATAJENJE SRCA: 
TAKO BLIZU, A TAKO DALEKO
J. Ostojić i H. Pintarić
Kronična opstruktivna plućna bolest (KOPB) i zatajenje srca među vodećim su uzrocima pobolijevanja i smrtnosti u 
svijetu. Unatoč brojnim poveznicama, kod bolesnika s kroničnom opstruktivnom plućnom bolešću zatajenje srca ostaje često 
neprepoznato, no vrijedi i obratno. Kod bolesnika s prethodno utvrđenom KOPB dijagnoza zatajenja srca se često postavlja 
prekasno, no vrijedi i obratno, ponajviše zbog vrlo sličnih simptoma i znakova bolesti poput zaduhe i intolerancije napora 
uslijed disfunkcije skeletne muskulature. Bolesnici s KOPB-om imaju viši rizik zatajenja srca, ali i češće hospitalizacije i 
smrtnost od bolesnika sa zatajenjem srca bez pridružene KOPB. Ehokardiografi ja, testovi plućne funkcije i određivanje 
 natriuretskih peptida trebaju biti neizostavni dio dijagnostičkog postupka i reevaluacije bolesnika uz bližu suradnju subspe-
cijalista kardiologa i pulmologa sa svrhom ne samo pouzdane dijagnoze, već i optimalnog pristupa liječenju bolesnika s često 
prisutnim komorbiditetima.
Ključne riječi: Plućna bolest, kronična opstruktivna – dijagnostika; Plućna bolest, kronična opstruktivna – terapija; Srčano 
 zatajivanje – dijagnostika; Ehokardiografi ja; Respiracija, ispitivanje funkcije
